SpringerLink
Log in

Prognostic significance of aberrant expression of CD markers in acute lymphoblastic leukemia

  • review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

Acute lymphoblastic leukemia (ALL) forms a heterogeneous group of disorders with a characteristic set of CD markers. Nowadays, these markers are used for the classification of hematopoietic malignancies and are a basis for diagnosis of leukemia. Unusual expression of CD markers as different immunophenotype of lymphoblasts is known as the aberrant expression of markers. The frequency of this phenomenon has been reported to be nearly 30% in different studies. Immunophenotype of precursor B‑cell leukemia involves the likely expression of myeloid CD markers (CD13 and CD33). In precursor T‑cell leukemia, myeloid markers (CD13 and CD33) are frequent but CD117 is rare. On the other hand, the presence of multiple translocations is also associated with a higher or lower level of aberrant markers that could be effective in changing the prognosis of patients. Further studies are needed to confirm the relationship between aberrant expression with prognosis and response to treatment of ALL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Suggs JL, Cruse JM, Lewis RE. Aberrant myeloid marker expression in precursor B‑cell and T‑cell leukemias. Exp Mol Pathol. 2007;83(3):471–3.

    Article  CAS  PubMed  Google Scholar 

  2. Lewis RE, Cruse JM, Sanders CM, Webb RN, Tillman BF, Beason KL, et al. The immunophenotype of pre-TALL/LBL revisited. Exp Mol Pathol. 2006;81(2):162–5.

    Article  CAS  PubMed  Google Scholar 

  3. Abdelhaleem M. Frequent but nonrandom expression of myeloid markers on de novo childhood acute lymphoblastic leukemia. Exp Mol Pathol. 2007;83(1):138–41.

    Article  CAS  PubMed  Google Scholar 

  4. Kavianpur M, Shahjahani M, Jaseb K, Kasar S, Saki N. Prognostic value and clinical significance of TCR rearrangements for MRD monitoring in ALL patients. Comp Clin Path. 2017;26:269. doi:10.1007/s00580-015-2207-8

    Google Scholar 

  5. Rossi JG, Bernasconi AR, Alonso CN, Rubio PL, Gallego MS, Carrara CA, et al. Lineage switch in childhood acute leukemia: an unusual event with poor outcome. Am J Hematol. 2012;87(9):890–7.

    Article  PubMed  Google Scholar 

  6. Bhushan B, Chauhan PS, Saluja S, Verma S, Mishra AK, Siddiqui S, et al. Aberrant phenotypes in childhood and adult acute leukemia and its association with adverse prognostic factors and clinical outcome. Clin Exp Med. 2010;10(1):33–40.

    Article  PubMed  Google Scholar 

  7. Sarma A, Hazarika M, Das D, Kumar RA, Sharma JD, Bhuyan C, et al. Expression of aberrant CD markers in acute leukemia: A study of 100 cases with immunophenoty** by multiparameter flowcytometry. Cancer Biomark. 2015;15(4):501–5.

    Article  CAS  PubMed  Google Scholar 

  8. Cruse JM, Lewis RE, Pierce S, Lam J, Tadros Y. Aberrant expression of CD7, CD56, and CD79a antigens in acute myeloid leukemias. Exp Mol Pathol. 2005;79(1):39–41.

    Article  CAS  PubMed  Google Scholar 

  9. Sharma RK, Purohit A, Somasundaram V, Mishra PC, Kotru M, Ranjan R, et al. Aberrant myeloid antigen co-expression is correlated with high percentages of CD34-positive cells among blasts of acute lymphoblastic leukemia patients: an Indian tertiary care center perspective. Blood Res. 2014;49(4):241–5.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Vitale A, Guarini A, Ariola C, Meloni G, Perbellini O, Pizzuti M, et al. Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial. Haematologica. 2007;92(3):342–8.

    Article  CAS  PubMed  Google Scholar 

  11. Guyotat D, Campos L, Shi Z, Charrin C, Treille D, Magaud J, et al. Myeloid surface antigen expression in adult acute lymphoblastic leukemia. Leukemia. 1990;4(9):664–6.

    CAS  PubMed  Google Scholar 

  12. Czuczman MS, Dodge RK, Stewart CC, Frankel SR, Davey FR, Powell BL, et al. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364. Blood. 1999;93(11):3931–9.

    CAS  PubMed  Google Scholar 

  13. Supriyadi E, Veerman AJP, Sutaryo, Purwanto I, vd Ven PM, Cloos J. Myeloid antigen expression in childhood acute Lymphoblastic leukemia and its relevance for clinical outcome in indonesian ALL-2006 protocol. J Oncol. 2012;2012:135186.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Preti HA, Huh YO, O’Brien SM, Andreeff M, Pierce ST, Keating M, et al. Myeloid markers in adult acute lymphocytic leukemia. Correlations with patient and disease characteristics and with prognosis. Cancer. 1995;76(9):1564–70.

    Article  CAS  PubMed  Google Scholar 

  15. Sobol RE, Mick R, Royston I, Davey FR, Ellison RR, Newman R, et al. Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia. N Engl J Med. 1987;316(18):1111–7.

    Article  CAS  PubMed  Google Scholar 

  16. Yenerel M, Atamer T, Yavuz A, Kucukkaya R, Besisik S, Aktan M, et al. Myeloid antigen expression provides favorable outcome in patients with adult acute lymphoblastic leukemia: a single-center study. Ann Hematol. 2002;81(9):498–503.

    Article  CAS  PubMed  Google Scholar 

  17. Swerdllow S, Campo E, Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.

    Google Scholar 

  18. Shahjahani M, Norozi F, Ahmadzadeh A, Shahrabi S, Tavakoli F, Asnafi AA, et al. The role of Pax5 in leukemia: diagnosis and prognosis significance. Med Oncol. 2015;32(1):1–8.

    Article  CAS  Google Scholar 

  19. Seegmiller AC, Kroft SH, Karandikar NJ, McKenna RW. Characterization of immunophenotypic aberrancies in 200 cases of B acute lymphoblastic leukemia. Am J Clin Pathol. 2009;132(6):940–9.

    Article  CAS  PubMed  Google Scholar 

  20. Golchin N, Khodadi E, Yaghooti SH, Jaseb K, Shahjahani M, Tavakolifar Y, et al. Immunophenotype, microRNA expression and cytogenetic characterization of acute leukemias of ambiguous lineage. Comp Clin Path. 2017;26:261. doi:10.1007/s00580-015-2134-8

    Google Scholar 

  21. Hussein S, Gill KZ, Sireci AN, Colovai AI, Small T, Emmons FN, et al. Aberrant T‑cell antigen expression in B lymphoblastic leukaemia. Br J Haematol. 2011;155(4):449–56.

    Article  CAS  PubMed  Google Scholar 

  22. Azad VF, Asl AAH, Tashvighi M, Mofrad NN, Haghighi M, Mehrvar A. CD7 aberrant expression led to a lineage switch at relapsed childhood acute pre-B lymphoblastic leukemia. Med Mol Morphol. 2016;49(1):53–6.

    Article  Google Scholar 

  23. Ahmed D, Ahmed TA, Ahmed S, Tipu HN, Wiqar MA. CD5-positive acute lymphoblastic leukemia. J Coll Physicians Surg Pak. 2008;18(5):310–1.

    PubMed  Google Scholar 

  24. Subira D, Roman A, Jimenez-Garofano C, Prieto E, Martinez-Delgado B, Aceituno E, et al. Brief report: CD19/CD5 acute lymphoblastic leukemia. Med Pediatr Oncol. 1998;31(6):551–2.

    Article  CAS  PubMed  Google Scholar 

  25. Pilozzi E, Pulford K, Jones M, Muller-Hermelink HK, Falini B, Ralfkiaer E, et al. Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma. J Pathol. 1998;186(2):140–3.

    Article  CAS  PubMed  Google Scholar 

  26. Borowitz MJ, Hunger SP, Carroll AJ, Shuster JJ, Pullen DJ, Steuber CP, et al. Predictability of the t (1; 19)(q23; p13) from surface antigen phenotype: implications for screening cases of childhood acute lymphoblastic leukemia for molecular analysis: a Pediatric Oncology Group study. Blood. 1993;82(4):1086–91.

    CAS  PubMed  Google Scholar 

  27. Foa R, Vitale A, Mancini M, Cuneo A, Mecucci C, Elia L, et al. E2A-PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features. Br J Haematol. 2003;120(3):484–7.

    Article  CAS  PubMed  Google Scholar 

  28. Van den Ancker W, Terwijn M, Westers T, Merle P, Van Beckhoven E, Dräger A, et al. Acute leukemias of ambiguous lineage: diagnostic consequences of the WHO2008 classification. Leukemia. 2010;24(7):1392.

    Article  PubMed  Google Scholar 

  29. Kim H‑J. Mixed-phenotype acute leukemia (MPAL) and beyond. Blood Res. 2016;51(4):215–6.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Wolach O, Stone RM. How I treat mixed-phenotype acute leukemia. Blood. 2015;125(16):2477–85.

    Article  CAS  PubMed  Google Scholar 

  31. Cascavilla N, Musto P, D’Arena G, Ladogana S, Matera R, Carotenuto M. Adult and childhood acute lymphoblastic leukemia: clinico-biological differences based on CD34 antigen expression. Haematologica. 1997;82(1):31–7.

    CAS  PubMed  Google Scholar 

  32. Drexler HG, Thiel E, Ludwig WD. Review of the incidence and clinical relevance of myeloid antigen-positive acute lymphoblastic leukemia. Leukemia. 1991;5(8):637–45.

    CAS  PubMed  Google Scholar 

  33. Putti MC, Rondelli R, Cocito MG, Arico M, Sainati L, Conter V, et al. Expression of myeloid markers lacks prognostic impact in children treated for acute lymphoblastic leukemia: Italian experience in AIEOP-ALL 88–91 studies. Blood. 1998;92(3):795–801.

    CAS  PubMed  Google Scholar 

  34. Sun T, Akalin A, Rodacker M, Braun T. CD20 positive T cell lymphoma: is it a real entity? J Clin Pathol. 2004;57(4):442–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Tiensiwakul P, Lertlum T, Nuchprayoon I, Seksarn P. Immunophenoty** of acute lymphoblastic leukemia in pediatric patients by three-color flow cytometric analysis. Asian Pac J Allergy Immunol. 1999;17(1):17–21.

    CAS  PubMed  Google Scholar 

  36. Boldt D, Kopecky K, Head D, Gehly G, Radich JP, Appelbaum FR. Expression of myeloid antigens by blast cells in acute lymphoblastic leukemia of adults. The Southwest Oncology Group experience. Leukemia. 1994;8(12):2118–26.

    CAS  PubMed  Google Scholar 

  37. Rai L, Casanova A, Moorman AV, Richards S, Buck G, Goldstone AH, et al. Antigen receptor gene rearrangements reflect on the heterogeneity of adult Acute Lymphoblastic Leukaemia (ALL) with implications of cell-origin of ALL subgroups – a UKALLXII study. Br J Haematol. 2010;148(3):394–401.

    Article  CAS  PubMed  Google Scholar 

  38. Amirghofran Z, Shamseddin A, Shahriari M. Prognostic value of myeloid antigen expression in acute lymphoblastic leukemia. Med J Islam Repub Iran. 2000;14(2):111–4.

    Google Scholar 

  39. Alkayed K, Khattab E, Madanat F. Aberrant T‑cell antigen expression in Jordanian children with B lymphoblastic leukemia. Hematol Oncol Stem Cell Ther. 2015;8(4):187–8.

    Article  PubMed  Google Scholar 

  40. Ng S, Ariffin W, Lin H, Chan L, Chin Y. Clinical features and treatment outcome of children with myeloid antigen coexpression in B‑lineage acute lymphoblastic leukemia: a study of 151 Malaysian children. J Trop Pediatr. 2000;46(2):73–8.

    Article  CAS  PubMed  Google Scholar 

  41. Ahmadzadeh A, Saedi S, Jaseb K, Asnafi AA, Alghasi A, Saki N. T‑cell acute lymphoblastic leukemia with del (7)(q11. 2q22) and aberrant expression of myeloid markers. Int J Hematol Oncol Stem Cell Res. 2013;7(4):40.

    PubMed  PubMed Central  Google Scholar 

  42. Sreedharanunni S, Kumar N, Khadwal ACD. Positive B lymphoblastic leukemia: report of a case with review of literature. Indian J Hematol Blood Transfus. 2016;32(1):1–4.

    Article  PubMed  Google Scholar 

  43. Mutreja D, Pati HP, Bansal D, Sharma RK, Jain S. Aberrant Immunophenotypic expression of CD5 in a case of B acute lymphoblastic leukemia: a case report. Indian J Hematol Blood Transfus. 2014;30(1):212–4.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Peterson MR, Noskoviak KJ, Newbury R. CD5-positive B‑cell acute lymphoblastic leukemia. Pediatr Dev Pathol. 2007;10(1):41–5.

    Article  PubMed  Google Scholar 

  45. Paietta E, Neuberg D, Richards S, Bennett JM, Han L, Racevskis J, et al. Rare adult acute lymphocytic leukemia with CD56 expression in the ECOG experience shows unexpected phenotypic and genotypic heterogeneity. Am J Hematol. 2001;66(3):189–96.

    Article  CAS  PubMed  Google Scholar 

  46. Dunphy CH, Chu JY. Aberrant CD2 expression in precursor-B acute lymphoblastic leukemia of childhood. Am J Hematol. 1996;52(3):224–6.

    Article  CAS  PubMed  Google Scholar 

  47. Cantu-Rajnoldi A, Putti MC, Schiro R, Biondi A, Cattoretti G, Valeggio C, et al. Biological and clinical features of B‑precursor childhood acute lymphoblastic leukemia showing CD2 and/or E‑rosette co-expression. Haematologica. 1992;77(5):384–91.

    CAS  PubMed  Google Scholar 

  48. Rahemtullah A, Longtine JA, Harris NL, Dorn M, Zembowicz A, Quintanilla-Fend L, et al. CD20+ T‑cell lymphoma: Clinicopathologic analysis of 9 cases and a review of the literature. Am J Surg Pathol. 2008;32(11):1593–607.

    Article  PubMed  Google Scholar 

  49. Yao X, Teruya-Feldstein J, Raffeld M, Sorbara L, Jaffe ES. Peripheral T‑cell lymphoma with aberrant expression of CD79a and CD20: a diagnostic pitfall. Mod Pathol. 2001;14(2):105–10.

    Article  CAS  PubMed  Google Scholar 

  50. Hashimoto M, Yamashita Y, Mori N. Immunohistochemical detection of CD79a expression in precursor T cell lymphoblastic lymphoma/leukaemias. J Pathol. 2002;197(3):341–7.

    Article  CAS  PubMed  Google Scholar 

  51. Baruchel A, Cayuela J, Ballerini P, Landman-Parker J, Cezard V, Firat H, et al. The majority of myeloid-antigen-positive (My+) childhood B‑cell precursor acute lymphoblastic leukaemias express TEL-AML1 fusion transcripts. Br J Haematol. 1997;99(1):101–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This paper is issued from the thesis of Neda Ketabchi, MSc student of hematology and blood banking. This work was financially supported by grant IR. AJUMS. REC. TH94/9 from vice chancellor for Research Affairs of Ahvaz Jundishapur University of Medical Sciences.

Author information

Authors and Affiliations

  1. Health research institute, Research Center of Thalassemia and Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

    Maria Kavianpour, Neda Ketabchi & Najmaldin Saki

Authors
  1. Maria Kavianpour
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neda Ketabchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Najmaldin Saki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Najmaldin Saki.

Ethics declarations

Conflict of interest

M. Kavianpour, N. Ketabchi, and N. Saki declare that they have no competing interests.

Ethical standards

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Authors’ contributions N. Saki conceived the manuscript and revised it; N. Saki, M. Kavianpour and N. Ketabchi wrote the manuscript and prepared the tables.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kavianpour, M., Ketabchi, N. & Saki, N. Prognostic significance of aberrant expression of CD markers in acute lymphoblastic leukemia . memo 10, 164–169 (2017). https://doi.org/10.1007/s12254-017-0324-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-017-0324-6

Keywords

Search

Navigation